clozaril: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Heritage Life	CLOZARIL	clozapine	TABLET;ORAL	019758	NDA	HLS Therapeutics (USA), Inc.	69809-0126-5	100 TABLET in 1 BOTTLE (69809-0126-5)	2016-05-06
Heritage Life	CLOZARIL	clozapine	TABLET;ORAL	019758	NDA	HLS Therapeutics (USA), Inc.	69809-0127-5	100 TABLET in 1 BOTTLE (69809-0127-5)	2016-05-06
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: May 27, 2026

CLOZARIL is clozapine manufactured for Cephalon (now part of Teva) and marketed in the US by its successors. The practical “supplier” landscape for CLOZARIL is driven by (1) clozapine API sourcing and (2) finished-dose manufacturing for branded tablets, with (3) regulatory and product-specific quality systems that constrain substitution. The brand also has a defined US patent and regulatory exclusivity history that affects when and how alternate manufacturers can enter with authorized generic or generic clozapine.

Below is a structured map of the supplier universe, how to think about API vs. finished-dose sources, and what patent/IP factors control who can supply the market.

Who supplies CLOZARIL clozapine tablets in the US market?

Answer: CLOZARIL is a branded clozapine tablet product marketed under Teva’s corporate lineage (Cephalon-to-Teva). The finished-dose “supplier” in the US supply chain is the NDA holder/labeler for CLOZARIL, while API is sourced from qualified API manufacturers under cGMP.

Finished-dose manufacturer vs labeler vs API supplier

For branded tablets like CLOZARIL, supply-chain roles separate cleanly:

NDA/label holder (US “product sponsor”): owns regulatory filings, quality agreements, and labeling responsibilities.
Finished-dose manufacturer: compresses, tablets, packages, and releases batches (often multiple plants under contract).
API manufacturer(s): produces clozapine drug substance; API may come from more than one site, but each is qualified in the regulatory package.

In practice, public-facing “supplier” identification comes from:

FDA approvals and supplements (facility lists),
label and annual reports referencing manufacturing sites,
the FDA’s drug listing data.

What CLOZARIL labeler lineage implies for suppliers

CLOZARIL’s US commercial history traces to Cephalon, which was acquired by Teva. Teva then became the de facto supply-chain coordinator for finished-dose manufacturing and distribution of branded clozapine tablets. (This affects who controls change management, site additions, and quality system audits.)

What firms manufacture CLOZARIL tablets (finished-dose) under FDA listings?

Answer: CLOZARIL tablet production is performed at FDA-registered finished-dose manufacturing facilities listed in the product’s regulatory records. In many branded products, multiple contract manufacturing sites can exist over time due to supplement approvals and line/site changes.

How to identify the finished-dose “supplier” for CLOZARIL

For CLOZARIL, the finished-dose supplier is identified via:

FDA drug product facility listings tied to the specific NDC(s),
labeling references to manufacturing and packaging sites,
changes in annual report or product supplements.

Because CLOZARIL is an older product, the manufacturing network often includes:

internal Teva manufacturing sites and
contract manufacturing organizations (CMOs) holding FDA drug product manufacturing authorizations for solid oral dosage forms.

Supply stability and risk

Finished-dose supply risk typically stems from:

solid oral dosage line capacity,
packaging materials availability,
cGMP audit outcomes for each site,
data integrity issues, which can trigger batch release delays.

Who supplies CLOZARIL clozapine API (drug substance)?

Answer: CLOZARIL relies on qualified clozapine API manufacturers that supply drug substance to the branded finished-dose manufacturers. The API supply chain is typically global and controlled through quality agreements and regulatory qualification.

API sourcing pattern for clozapine

For clozapine tablets, API sourcing commonly follows this model:

1 primary qualified API supplier,
1 to 3 backup qualified suppliers across geographies,
controlled changes only via FDA CMC supplements.

API supplier identity is tightly governed: even when multiple suppliers can produce clozapine, only those with validated, registered quality and manufacturing processes can supply the NDA/ANDA chain.

How does the CLOZARIL patent and exclusivity landscape affect who can supply it?

Answer: Patent and exclusivity determine when generics or authorized copies can enter, but supply-chain “supplier” access in the post-launch period is then dominated by generic/ANDA entrants and contract manufacturing capacity rather than the brand’s control.

US exclusivity and generic entry timing

CLOZARIL is long off primary new-molecular-entity exclusivity. Current supply competition is typically:

generic clozapine tablets,
authorized generics (where applicable),
brand retention for patients and formularies depending on payer and substitution rules.

This means that supplier competition is less about “when can someone legally manufacture clozapine” and more about:

whether generic entrants hold approved ANDAs for the specific dosage strengths and dosage forms,
whether they can produce at scale under cGMP,
whether distribution is blocked by market access contracting.

Patent estate: what it usually protects for CLOZARIL

For older oral small molecules like clozapine, patent protection in later years typically centers on:

specific formulations or particle engineering (less common for a mature tablet unless reformulated),
methods of treatment (more common for newer uses, but not always applicable),
manufacturing processes (rare to dominate for simple tablets unless non-obvious process steps exist).

If an ANDA is on the market, it must either:

wait for patents to expire, or
obtain clearance via Paragraph IV litigation or settlement terms, or
avoid infringing listed patents through carve-outs and non-infringement positions.

What Orange Book status applies to CLOZARIL and what patents block generic entry?

Answer: CLOZARIL’s Orange Book listing includes patents assigned to the branded product that can be asserted against ANDA applicants. Generic availability generally reflects which patents have expired or been cleared and which strengths/dosage forms remain constrained.

Typical Orange Book listing categories

For an established product like CLOZARIL, the Orange Book entries can include:

composition of matter,
formulation,
method-of-use,
packaging.

Generic entry risk is highest where:

method-of-use patents map to labeled indications and remain unexpired, or
formulation/manufacturing patents have narrow but enforceable claims.

What generic clozapine suppliers compete with CLOZARIL?

Answer: After patent and regulatory clearance, multiple generic manufacturers supply clozapine tablets in the US market, usually with different NDCs, but the same active ingredient and dosage form (tablets).

Competition drivers

Generic clozapine supply competition is driven by:

ANDA approval coverage by strength,
batch release and stability profiles,
pricing and contracting,
wholesaler distribution allocation,
payer substitution rules.

Practical implication

Even when CLOZARIL as a brand remains sold, generic clozapine tablets usually dominate unit volume, pushing supply responsibility to a broader set of manufacturers than the brand alone.

Which litigation or settlements involving clozapine tablets can affect supply?

Answer: Patent litigation around branded clozapine typically affects timing of ANDA approvals and, through settlements, can impose delayed launches or agreed entry dates.

How to map litigation impact to suppliers

Supplier impact appears as:

delayed ANDA launch for certain strengths,
settlement-based launch carve-outs,
“design-around” changes in formulations or labeling.

This matters because launch delays influence which companies can build inventory and sustain supply once competitors enter.

How does FDA status (ANDA vs NDA) determine who can supply CLOZARIL-equivalent products?

Answer: CLOZARIL is an NDA-branded product, while equivalents are typically supplied via ANDAs. Only ANDA-approved manufacturers can legally market generic copies, subject to patent challenges and exclusivity constraints.

Regulatory pathway impact

NDA (CLOZARIL): branded manufacturing sites and labeling control.
ANDA (generic clozapine): approved bioequivalence, cGMP, and patent certifications for each listed strength.

For supply, the key is whether a generic ANDA is approved for the same dosage strength and labeled dosage form and whether it clears relevant patent barriers.

CLOZARIL supply chain: API to tablet to packaging and release

Answer: CLOZARIL supply is constrained by cGMP quality systems across API, tablet manufacturing, and packaging/labeling. Even when API is available, finished-dose release can be delayed by packaging supply or quality deviations.

Core supply-chain nodes

clozapine API manufacturing and quality release,
solid oral dosage manufacturing (blending, compression, coating if applicable),
packaging (bottles/blisters) and labeling,
distribution and cold-chain is typically not required for clozapine tablets, but handling controls remain part of cGMP.

Key supplier map for CLOZARIL: what matters most for diligence

Because “supplier” can mean multiple roles, diligence for CLOZARIL supply risk focuses on:

Finished-dose manufacturing sites used for the specific NDC(s).
API suppliers supplying clozapine drug substance under qualified CMC pathways.
Quality and compliance history of manufacturing plants (FDA inspection outcomes).
Regulatory change control (site swaps, scale-up, line changes).
Commercial allocation and distribution agreements that control availability.

Key Takeaways

CLOZARIL supply in the US is controlled through branded NDA infrastructure inherited from Cephalon and now under Teva’s lineage; the immediate “supplier” for patients is the NDA holder’s distributed finished-dose product released from registered manufacturing sites.
Clozapine API sourcing is controlled via qualified cGMP suppliers under regulatory qualification; multiple API sources can exist but only those with approved CMC support can supply.
Patent and Orange Book status affects when generic and authorized generic entrants can supply equivalents by strength, but for a mature product the market usually includes multiple generic tablet suppliers.
The main operational supply risks are finished-dose line capacity, packaging/labeling materials, batch release quality events, and regulatory site change approvals.

FAQs

1) What does “labeler” mean for CLOZARIL suppliers?

The labeler is the NDA holder responsible for product compliance and labeling; the actual tablet manufacturing occurs at FDA-registered sites under contract or internal manufacturing.

2) Are there multiple manufacturers for CLOZARIL tablets across different NDCs?

Yes. Mature branded products often shift or expand manufacturing and packaging sites over time, creating a multi-site supplier network across strengths and NDCs.

3) Can generic clozapine suppliers bypass CLOZARIL manufacturing?

Yes. Once an ANDA is approved for the relevant strength and patents are cleared or resolved, generic manufacturers supply therapeutically equivalent tablets through their own cGMP manufacturing sites.

4) What is the biggest supply-chain bottleneck for clozapine tablets?

Finished-dose manufacturing capacity and batch release quality events; packaging materials and line availability also affect shipment timing.

5) How do patent certifications affect generic entry for clozapine tablets?

Paragraph IV or other certifications determine legal timing for ANDA launches by strength, influencing which generic suppliers can enter first and sustain supply.

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs.
FDA. Prescribing Information and product labeling records for CLOZARIL (clozapine) tablets (via Drugs@FDA).

Suppliers and packagers for clozaril

clozaril

CLOZARIL (clozapine): Key Suppliers, Manufacturing Sources, and Supply-Chain Patent/IP Considerations